APL patient with positive HBV / HCV / HIV serology, latent TB, or active uncontrolled inf...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-APL-INFECTION-SCREENING |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-APL |
| Sources | SRC-ELN-APL-2019 SRC-NCCN-AML-2025 |
Red Flag Origin
| Definition | APL patient with positive HBV / HCV / HIV serology, latent TB, or active uncontrolled infection — needs antiviral prophylaxis before initiating consolidation; ATRA initiation should NOT wait for these results |
|---|---|
| Clinical direction | hold |
| Category | infection-screening |
Trigger Logic
{
"any_of": [
{
"finding": "hbsag",
"value": "positive"
},
{
"finding": "anti_hbc_total",
"value": "positive"
},
{
"finding": "hcv_rna",
"value": "positive"
},
{
"finding": "hiv_status",
"value": "positive"
},
{
"finding": "active_uncontrolled_infection",
"value": true
}
],
"type": "composite"
}
Notes
Direction "hold" — surfaces a pre-consolidation prerequisite. APL induction (ATRA + ATO ± idarubicin) does not delay for serology; consolidation cycles use anthracycline-containing regimens that warrant HBV-active prophylaxis if serologically at risk. STUB — requires clinical co-lead signoff.
Used By
Algorithms
ALGO-APL-1L- ALGO-APL-1LALGO-APL-2L- ALGO-APL-2L
Indications
IND-APL-RELAPSED-GEMTUZUMAB- IND-APL-RELAPSED-GEMTUZUMABIND-APL-SALVAGE-ATRA-ATO- IND-APL-SALVAGE-ATRA-ATO